The efficacy and safety of terbinafine in children

Dermatologic Clinics

Volumn 21, Issue 3, 2003, Pages 511-520

  Gupta, Aditya K ^a,b,d   Cooper, Elizabeth A ^b   Lynde, Charles W ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; KETOCONAZOLE; PLACEBO; TERBINAFINE;

ABDOMINAL PAIN; ANOREXIA; ANTIFUNGAL ACTIVITY; BIOAVAILABILITY; CHILD; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; EOSINOPHILIA; FEVER; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERESTHESIA; LEUKOPENIA; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; ONYCHOMYCOSIS; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SOMNOLENCE; TASTE DISORDER; TINEA CAPITIS; URTICARIA; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 0042514876     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00029-9     Document Type: Review

References (76)

1. Lobato MN, Vugia DJ, Frieden IJ. Tinea capitis in California children: a population-based study of a growing epidemic. Pediatrics 1997;99:551-4.
2. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989;14:110-3.
3. Novartis Pharmaceuticals. Terbinafine (Lamisil) package insert. May 2001. NJ: Novartis Pharmaceuticals; 2001.
4. Leyden J. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol 1998;38:S42-7.
5. Faergemann J. Pharmacokinetics of terbinafine. Rev Contemp Pharmacother 1997;8:289-97.
6. Faergemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum comeum, dermisepidermis (without stratum comeum), hair, sebum and eccrine sweat. Acta Derm Venereol 1990;71:322-6.
7. Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990;23(4 pt 2):782-5.
8. Canadian Pharmacists Association. Lamisil package insert. In: Repchinsky C, editor. Compendium of pharmaceuticals and specialties. 36th edition. Toronto: Webcom Limited; 2001. p. 803-5.
9. Terbinafine. Systemic. In: USP DI editorial group. Volume I - drug information for the health care professional. 21st edition. Tauton: MICROMEDEX Thomson Healthcare; 2001. p. 2786-8.
10. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992;39:2-7.
11. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Contemp Pharmacother 1997;8:275-87.
12. Haroon TS, Hussain I, Aman S, Jahangir MJ, Kazmi AH, Sami AR, et al. A randomized double-blind comparative study of terbinafine for 1,2 and 4 weeks in tinea capitis. Br J Dermatol 1996;135:86-8.
13. Clayton YM. In vitro activity of terbinafine. Clin Exp Dermatol 1989;14:101-3.
14. Vickers AEM, Sinclair JR, Zollinger M, Heitz F, Glanzel U, Johanson L, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 1999;27:1029-38.
15. Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos 1999;27:770-5.
16. Long CC, Hill SA, Thomas RC, Johnston A, Smith SG, Kendall F, et al. Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. J Invest Dermatol 1994;102:740-3.
17. Gupta AK, Summerbell RC. Increased incidence of Trichophyton tonsurans tinea capitis in Ontario, Canada between 1985 and 1996. Med Mycol 1998;36:55-60.
18. Wilmington M, Aly R, Frieden IJ. Trichophyton tonsurans tinea capitis in the San Francisco Bay area: increased infection demonstrated in a 20-year survey of fungal infections from 1974-1994. J Med Vet Mycol 1996;34:285-7.
19. Alvi KH, Iqbal N, Khan KA, Haroon TS, Hussain I, Aman S, et al. A randomized, double-blind trial of the efficacy and tolerability of terbinafine once daily in the treatment of tinea capitis. In: Shuster S, Jafary MH, editors. Terbinafine in the treatment of superficial fungal infections. London: Royal Society of Medicine Services; 1993. p. 35-40.
20. Baudraz-Rosselet F, Monod M, Jaccoud S, Frenk E. Efficacy of terbinafine treatment of tinea capitis in children varies according to the dermatophyte species. Br J Dermatol 1996;135:1003-17.
21. Bruckbauer HR, Hofmann H. Systemic antifungal treatment of children with terbinafine. Dermatology 1997;195:134-6.
22. Caceres-Ríos H, Rueda M, Ballona R, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J Am Acad Dermatol 2000;42:80-4.
23. Crespi HG. Efficacy and tolerance of oral terbinafine for the treatment of tinea capitis in children [abstract]. Australas J Dermatol 1997;38(suppl 2):271-2.
24. de Freitas C, Marote J, Faria A, Fernandes A, Sequeira H, Rodrigo G. Tinea capitis in children of Caniçal, Madeira Island, Portugal: treatment with terbinafine. Novartis, No. 10700.
25. del Carmen Padilla Desgarennes M, Godoy MR, Palencia AB. Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans. J Am Acad Dermatol 1996;35:114-6.
26. Del Palacio A, Cuetara S, Valle A. Terbinafine (Lamisil) therapy for Microsporum canis scalp ringworm. Clin Exp Dermatol 1998;23:142-3.
27. Dragoš V, Lunder M. Lack of efficacy of 6-week treatment with oral terbinafine for tinea capitis due to Microsporum canis in children. Pediatr Dermatol 1997;14:46-8.
28. Elewski BE. Treatment of tinea capitis: should terbinafine replace griseofulvin? J Dermatol Treat 1998;9(suppl 1):S9-11.
29. Friedlander SF, Aly R, Krafchik B, Blumer J, Honig P, Wraith LA, et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel group duration-finding study. Pediatrics 2002;109:602-7.
30. Fuller LC, Smith CH, Cerio R, Marsden RA, Midgley G, Beard AL, et al. A randomized comparison of 4 weeks of terbinafine versus 8 weeks of griseofulvin for the treatment of tinea capitis. Br J Dermatol 2001;144:321-7.
31. Gargoom AM, Duweb GA. Terbinafine "Lamisil" in the treatment of tinea capitis [abstract]. Australas J Dermatol 1997;38(suppl 2):284.
32. Gruseck E, Splanemann V, Bleck O, Ring J, Abeck D. Oral terbinafine in tinea capitis in children. Mycoses 1996;39:237-40.
33. Gupta AK, Adam P, Dlova N, Lynde CW, Hofstader S, Morar N, et al. Therapeutic options for the treatment of tinea capitis: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole or fluconazole. Pediatr Dermatol 2001;18:433-8.
34. Gupta AK, Adam P. Terbinafine pulse therapy is effective in tinea capitis. Pediatr Dermatol 1998;15:66-8.
35. Hamm H, Schwinn A, Bräutigam M, Weidinger G. Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species. Br J Dermatol 1999;140:480-2.
36. Haroon TS, Hussain I, Mahmood A, Nagi AH, Ahmad I, Zahid M. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol 1992;126(suppl 39):47-50.
37. Haroon TS, Hussain I, Aman S, Nagi AH, Ahmad I, Alvi KH, et al. A randomized, double-blind comparative study of terbinafine (Lamisil) versus griseofulvin in tinea capitis. In: Hay RJ, editor. International perspective on Lamisil. London: CCT Healthcare Communications; 1994. p. 67-72.
38. Herranz P, de Lucas R, Vidaurrazaga C, Pizarro A, Mayor M, Buron I, et al. Tinea capitis in children: treatment with terbinafine. Ann Dermatol Venereol 1998;125(suppl 1):1S134-5.
39. Jahangir M, Hussain I, Ul Hasan M, Haroon TS. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 1998;139:672-4.
40. Jones TC, Gansland J, Williams TG. A clinical review of the efficacy and tolerability of terbinafine (Lamisil) in children with tinea capitis. J Eur Acad Dermatol Venereol 1998;11(suppl 2):S231.
41. Krafchik B, Pelletier J. An open study of tinea capitis in 50 children treated with a 2-week course of oral terbinafine. J Am Acad Dermatol 1999;41:60-3.
42. Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis. J Am Acad Dermatol 1997;37:272-3.
43. Lipozencic J, Skerlev M, Orofino-Costa R, Horvath A, Chouela E, Gourmala N, et al. A randomized, double-blind, parallel-group duration finding study of oral terbinafine in children with tinea capitis due to Microsporum species. Br J Dermatol 2002;146:816-23.
44. Memisoglu HR, Erboz S, Akkaya S, Akan T, Aksungur VL, Uenal I, et al. Comparative study of the efficacy and tolerability of 4 weeks of terbinafine therapy with 8 weeks of griseofulvin therapy in children with tinea capitis. J Dermatol Treat 1999;10:189-93.
45. Momeni AZ, Shadzi S, Chaedgani M, Aminjavaheri M. Efficacy of oral terbinafine treatment in tinea capitis [abstract]. Australas J Dermatol 1997;38(suppl 2):98.
46. Nejjam F, Zagula M, Cabiac MD, Guessous N, Humbert H, Lakhdar H. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol 1995;132:98-105.
47. Peharda V, Kastelan M, Cabrijan L, Saftic M, Gruber F. Terbinafine in the treatment of tinea capitis. Acta Derm Venereol 1998;7:164-6.
48. Pierini AM, Soliani A, Hernandez M, Garcia-Diaz R, Gonzalez MT, Santos P. Treatment of tinea capitis due to Microsporum canis with oral terbinafine: 40 cases. Ann Dermatol Venereol 1998;125(suppl 1):1S133.
49. Ravenscroft J, Goodfield MJD, Evans EGV. Trichophyton tonsurans tinea capitis and tinea corporis: treatment and follow-up of four affected family members. Pediatr Dermatol 2000;17:407-9.
50. Schwinn A, Hamm H, Braeutigam M, Weidinger G. What is the best approach to treat tinea capitis with terbinafine? Australas J Dermatol 1997;38(suppl 2):70.
51. Talarico Filho S, Arruda LHF, Cuce LC, Foss NT, Gontijo B, Marques SA, et al. Efficacy and tolerability of Lamisil (terbinafine) in the treatment of children with tinea capitis. J Eur Acad Dermatol Venereol 1995;5(suppl 1):S172.
52. Talarico Filho S, Cucé LC, Foss NT, Marques SA, Santamaria JR. Efficacy, safety and tolerability of terbinafine for tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1, 2 and 4 weeks. J Eur Acad Dermatol Venereol 1998;11:141-6.
53. Romero G, Garrido JA, Cortina P, Garcia-Bracamonte B, Romero MD. Efficacy of oral terbinafine in children with tinea capitis caused by Microsporum canis. J Eur Acad Dermatol Venereol 1998;11(suppl 2):S236.
54. Koumantaki E, Kakourou T, Rallis E, Riga P, Georgalla S. Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr Dermatol 2001;18:339-42.
55. Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, Shear NH, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997;36:395-402.
56. Suarez S, Friedlander SF. Antifungal therapy in children: an update. Pediatr Ann 1998;27:177-84.
57. Ungpakom R, Reangchainam S, Kullavanijaya P. Onychomycosis in a 2-year-old child successfully treated with oral terbinafine. J Am Acad Dermatol 1998;39:654-5.
58. Goulden V, Goodfield MJD. Treatment of childhood dermatophyte infections with oral terbinafine. Pediatr Dermatol 1995;12:53-4.
59. Gupta AK, Del Rosso JQ. Management of onychomycosis in children. Postgrad Med 1999;Spec.No:31-7.
60. Cox NH, Irving B. Cutaneous "ringworm" lesions of Scopulariopsis brevicaulis. Br J Dermatol 1993;129:726-8.
61. Bruynzeel I, Starink TM. Granulomatous skin infection caused by Scopulariopsis brevicaulis. J Am Acad Dermatol 1998;39:365-7.
62. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992;126(suppl 39):61-9.
63. Shenep JL, English BK, Kaufman L, Pearson TA, Thompson JW, Kaufman RA, et al. Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis 1998;27:1388-93.
64. Bahamdan KA, Tallab TM, Johargi H, Mazen Nourad M, Ibrahim K, Hameed El Sherbini A, et al. Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study [abstract]. Int J Dermatol 1997;36:59-60.
65. Wilmer A, Wollina U. Oral terbinafine in the treatment of griseofulvin-resistant tinea capitis et faciei et corporis in a 10-month-old girl. Acta Derm Venereol 1998;78:314.
66. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine. Results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997;133:1213-9.
67. Friedlander SF, Skerlev M, Lipozencic J, Bretz F, Emady-Azar S, Wraith LA, et al. Relationship between terbinafine dose and complete cure rate in tinea capitis: analysis of phase II randomized trials. J Eur Acad Derm Venereol 2001;15(suppl 2):221.
68. Committee on Infectious Diseases. Tinea capitis. In: Peter G, editor. Red book: report of the Committee on Infectious Diseases. 24th edition. Chicago: American Academy of Pediatrics; 1997. p. 523-5.
69. Burkhart CG. Coffee grinders assist pediatric dosing. Cutis 2000;65:276.
70. Cardindale V, editor. Drug topics red book pharmacy's fundamental reference. Montvale, NJ: Medical Economics Company; 2001. p. 32, 40, 45, 64.
71. Babel DE, Rogers AL, Beneke ES. Dermtophytosis of the scalp: incidence, immune response, and epidemiology. Mycopathologia 1990;109:69-73.
72. Frieden IJ. Tinea capitis: asymptomatic carriage of infection. Pediatr Infect Dis J 1999;18:186-90.
73. Greer DL. Treatment of symptom-free carriers in management of tinea capitis. Lancet 1996;348:350.
74. Neil G, Hanslo D, Buccimazza S, Kibel M. Control of the carrier state of scalp dermatophytes. Pediatr Infect Dis J 1990;9:57-8.
75. Pomeranz AJ, Sabnis SS, McGrath GJ, Esterly NB. Asymptomatic dermatophyte carriers in the households of children with tinea capitis. Arch Pediatr Adolesc Med 1999;153:483-6.
76. Williams JV, Honig PJ, McGinley KJ, Leyden JJ. Semiquantitative study of tinea capitis and the asymptomatic carrier state in inner-city school children. Pediatrics 1995;96(2 pt 1):265-7.